2017
The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance, and Body Composition in Postmenopausal American Women: An Ancillary Study from a Multicenter Protein Supplementation Trial
Stojkovic V, Simpson CA, Sullivan RR, Cusano AM, Kerstetter JE, Kenny AM, Insogna KL, Bihuniak JD. The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance, and Body Composition in Postmenopausal American Women: An Ancillary Study from a Multicenter Protein Supplementation Trial. Nutrients 2017, 9: 484. PMID: 28492492, PMCID: PMC5452214, DOI: 10.3390/nu9050484.Peer-Reviewed Original ResearchConceptsMarkers of inflammationInsulin resistanceGI/GLBody compositionAncillary studiesLean massPRO groupSignificant associationGlycemic load dietDouble-blind trialFat mass ratioTotal lean massTotal fat massPostmenopausal American womenTrunk lean massAge-related alterationsWhey protein supplementLoad dietInflammatory markersSerum CRPChronic inflammationIL-6Fat massSupplementation trialBone density
2015
The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance and Body Composition in Postmenopausal Women
Bihuniak J, Stojkovic V, Simpson C, Sullivan R, Cusano A, Insogna K. The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance and Body Composition in Postmenopausal Women. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.lb235.Peer-Reviewed Original ResearchMarkers of inflammationGI/GLInsulin resistanceBody compositionPostmenopausal womenLean massPRO groupGlycemic load dietTruncal lean massLow-grade inflammationTotal lean massTotal fat massLean body massWhey protein supplementLoad dietSerum CRPHigher BMIFood recordsIL-6Fat massChronic illnessInflammationOlder adultsFat ratioMonths
2007
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism
Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.Peer-Reviewed Original ResearchConceptsNuclear factor-kappaB ligandPrimary hyperparathyroidismBone lossReceptor activatorTotal femurIL-6Bone resorptionIL-6 soluble receptorMild primary hyperparathyroidismBone mineral densitySoluble receptor activatorMechanism of actionIL-6sRSRANKL levelsSerum levelsBone turnoverMineral densityCytokine systemSoluble receptorHyperparathyroidismNormal rangeSkeletal responsivenessBiochemical markersPatientsGreater risk
2002
Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism
Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-4951. PMID: 12414855, DOI: 10.1210/jc.2001-011814.Peer-Reviewed Original ResearchConceptsBone lossIL-6sRTotal femurIL-6IL-6 soluble receptorPrimary hyperparathyroidism resultsYearly bone lossSubset of patientsUntreated hyperparathyroidismDisease activityPrimary hyperparathyroidismUpper tertileCytokine axisHyperparathyroidismSoluble receptorPatientsBiochemical markersClassical biochemical markersWhole groupFemurPredict rateGreater rateRecent studiesTertileGroupEvidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
2001
IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo. Endocrinology 2001, 142: 3850-3856. DOI: 10.1210/en.142.9.3850.Peer-Reviewed Original ResearchCirculating levels of IL-6Levels of IL-6IL-11IL-6Circulating levelsBone resorptionSteady state mRNA levelsOsteoclast formationFive-day infusionHuman PTH-(1-84Pretreatment of cellsIL-11 levelsResponse to PTHIL-11 productionIncreased osteoclast formationIL-6 levelsPTH-(1-84Saos-2 cellsParathyroid adenomectomyDown-regulationProduction in vitroPrimary hyperparathyroidismPTH excessProduction in vivoSerum levelsIL-6 negatively regulates IL-11 production in vitro and in vivo.
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 2001, 142: 3850-6. PMID: 11517162, DOI: 10.1210/endo.142.9.8368.Peer-Reviewed Original ResearchConceptsIL-11 productionIL-6IL-11Bone resorptionOsteoclast formationIL-6 levelsIL-11 levelsFive-day infusionPTH excessPrimary hyperparathyroidismSerum levelsResorptive responseParathyroid adenomectomyPretreatment of cellsHuman PTHNonimmune serumPTHEffect of pretreatmentMRNA levelsSteady-state mRNA levelsPatientsCytokinesHuman osteoblast-like cellsResorptionSaos-2 cells
2000
Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*
Masiukiewicz U, Mitnick M, Grey A, Insogna K. Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*. Endocrinology 2000, 141: 2526-2531. DOI: 10.1210/en.141.7.2526.Peer-Reviewed Original ResearchCirculating levels of IL-6Levels of IL-6PTH-induced bone resorptionEstrogen-deficient stateIL-6Circulating levelsIL-6 productionPTH infusionEstrogen withdrawalBone resorptionResponse to PTH infusionChronic PTH excessEstrogen-replete conditionsTreated with PTHBone turnover markersInfusion of PTHBone resorption markersResponse to PTHEffect of PTHAbsence of estrogenRelease of IL-6Short-term infusionEstrogen-treated animalsInterleukin (IL)-6Collagen cross-linking